Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Mymd Pharmaceuticals Inc
(NQ:
MYMD
)
2.060
-0.030 (-1.44%)
Streaming Delayed Price
Updated: 9:35 AM EDT, May 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Mymd Pharmaceuticals Inc
< Previous
1
2
Next >
MyMD Pharmaceuticals Investment Company Oravax Medical Signs Cooperation and Purchase Agreement for Initial Pre-Purchase of 10 Million Doses of Oral COVID-19 Vaccine to be Commercialized in Southeast Asia
December 29, 2021
From
MyMD Pharmaceuticals, Inc.
Via
Business Wire
MyMD Pharmaceuticals to Participate in Two Investor Conferences During December 2021
December 01, 2021
From
MyMD Pharmaceuticals, Inc.
Via
Business Wire
MyMD Pharmaceuticals Announces Issuance of U.S. Patent Covering Lead Drug Candidate MYMD-1 in a Method of Extending Lifespan
November 23, 2021
From
MyMD Pharmaceuticals, Inc.
Via
Business Wire
MyMD Pharmaceuticals Investment Company Oravax Medical and Genomma Lab Announce Joint Venture to Develop and Commercialize Oral COVID-19 Vaccine in Mexico and Drive Business Development in Latin America
November 18, 2021
From
MyMD Pharmaceuticals, Inc.
Via
Business Wire
MyMD Pharmaceuticals Receives FDA IND Clearance to Begin Phase 2 Trial of MYMD-1 for Extending Healthy Lifespan
November 16, 2021
From
MyMD Pharmaceuticals, Inc.
Via
Business Wire
MyMD Pharmaceuticals President Chris Chapman, M.D. Named Medical Honoree of the Year by the Arthritis Foundation
October 26, 2021
From
MyMD Pharmaceuticals, Inc.
Via
Business Wire
MyMD Pharmaceuticals to Discuss its Novel Therapies for Aging and Related Diseases at the Dawson James Securities 6th Annual Small Cap Growth Conference on October 21
October 19, 2021
From
MyMD Pharmaceuticals, Inc.
Via
Business Wire
MyMD Pharmaceuticals to Detail its Two Upcoming Phase 2 Trials at the Benzinga Rising Stars: Catalytic Small Cap Growth Conference on October 7
October 05, 2021
From
MyMD Pharmaceuticals, Inc.
Via
Business Wire
MyMD Pharmaceuticals Announces New Data Demonstrating 8,000 Times Higher Potency of Novel Synthetic Supera-CBD over Plant-Derived CBD
September 22, 2021
From
MyMD Pharmaceuticals, Inc.
Via
Business Wire
MyMD Pharmaceuticals Announces Fourth Quarter 2021 Initiation of Phase 2 Clinical Trial of MYMD-1 for Extending Healthy Lifespan
September 13, 2021
From
MyMD Pharmaceuticals, Inc.
Via
Business Wire
MyMD Pharmaceuticals to Present its Novel Therapeutic Platforms for Extending Healthy Lifespan at the H.C. Wainwright 23rd Annual Global Investment Conference September 13-15
September 09, 2021
From
MyMD Pharmaceuticals, Inc.
Via
Business Wire
MyMD Pharmaceuticals Announces Issuance of U.S. Patent for Use of Lead Candidate MYMD-1 for Treating Fibrosis and Asthma
August 24, 2021
From
MyMD Pharmaceuticals, Inc.
Via
Business Wire
MyMD Pharmaceuticals Announces Issuance of U.S. Patent for Synthetic Cannabinoid Compounds for Treating Neuroinflammatory and Neurodegenerative Diseases
August 10, 2021
From
MyMD Pharmaceuticals, Inc.
Via
Business Wire
MyMD Pharmaceuticals Subsidiary Oravax Medical Preparing to Commence Clinical Trials for Oral COVID-19 Vaccine
August 10, 2021
From
MyMD Pharmaceuticals, Inc.
Via
Business Wire
MyMD Pharmaceuticals’ Lead Compound MYMD-1 Shown to Suppress a Major Cause of Death in COVID-19 in Human Cell Study
August 05, 2021
From
MyMD Pharmaceuticals, Inc.
Via
Business Wire
MyMD Pharmaceuticals’ Lead Compound MYMD-1 Shows Commonality in Comparative Study with FDA-Approved Anti-Inflammatory and Anti-Autoimmune Drugs Used for Arthritis, Colitis and Dermatitis
July 27, 2021
From
MyMD Pharmaceuticals, Inc.
Via
Business Wire
MyMD Pharmaceuticals Announces New Data from Comparative Study on Lead Compound MYMD-1
July 07, 2021
From
MyMD Pharmaceuticals, Inc.
Via
Business Wire
MyMD Pharmaceuticals Set to Join Russell Microcap® Index
June 07, 2021
From
MyMD Pharmaceuticals, Inc.
Via
Business Wire
MyMD Pharmaceuticals Appoints David Rini, Professor at the Johns Hopkins School of Medicine, to Scientific Advisory Board
May 17, 2021
From
MyMD Pharmaceuticals, Inc.
Via
Business Wire
MyMD Pharmaceuticals Schedules Business Update Conference Call
May 12, 2021
From
MyMD Pharmaceuticals, Inc.
Via
Business Wire
Johns Hopkins Medicine Researchers to Present Data on MyMD Pharmaceuticals’ Supera-CBD at the 3rd Annual Neuroimmunology Drug Development Summit
April 28, 2021
From
MyMD Pharmaceuticals, Inc.
Via
Business Wire
MyMD Pharmaceuticals Announces Issuance of Allowance from United States Patent and Trademark Office for Synthetic Cannabinoid Compounds
April 22, 2021
From
MyMD Pharmaceuticals, Inc.
Via
Business Wire
MyMD Pharmaceuticals Begins Trading on Nasdaq
April 19, 2021
From
MyMD Pharmaceuticals, Inc.
Via
Business Wire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.